Skip to main content

Table 1

From: Treating to target of minimal disease activity and normal function in polyarticular juvenile idiopathic arthritis with adalimumab: analysis from a phase 3 clinical trial

n (%)

Minimal Disease Activity

 

ADA Continuation

PBO

P-value

 

+MTX

-MTX

+MTX

-MTX

 

Week 16

28 (37.3)

19 (33.9)

NA

NA

NA

Week 48

19 (76.0)

14 (56.6)

15 (62.5)

13 (68.4)

0.8919

Week 88

26 (83.9)

20 (76.9)

14 (50.0)

13 (65.0)

0.0075

 

Minimal Disease Activity with Normal Function

Week 16

21 (28.0)

15 (26.8)

NA

NA

NA

Week 48

17 (68.0)

12 (48.0)

15 (62.5)

13 (68.4)

0.5155

Week 88

24 (77.4)

17 (65.4)

14 (50.0)

11 (55.0)

0.0362